Indo Us Biotech Limited Approves Unaudited Financial Results for Quarter Ended June 30, 2026
Indo Us Biotech Limited has announced the approval of its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors reviewed and approved these results, which were accompanied by limited review reports from the company's Statutory Auditors.The Company operates in the Seed Cultivation, Processing & Trading segment.
Financial Performance Summary
The unaudited financial statement details show key figures for the quarter ended June 30, 2026. The financial results have been examined and approved by the Board of Directors and the Audit Committee.Key metrics from the standalone unaudited financial statements are presented below:
| Metric | Value (Qtr ended Jun 30, 2026) |
|---|---|
| Total Income | 12.38 |
| Net Profit / (Loss) for the period/year | 3,003.35 |
The financial statements were subjected to a Limited Review Report by independent Chartered Accountants, Bhagat & Associates. The company expressed an unmodified opinion on these results.
Auditor's Limited Review Report
Based on their review, nothing came to the attention of the Independent Auditors that caused them to believe that the accompanying unaudited financial results contained any material misstatement or lacked necessary disclosure required by applicable accounting standards.The audit process followed the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," and was conducted in accordance with Ind-AS 34 -Interim Financial Reporting.
INDOUS Stock Price Movement
On Wednesday, Indo Us Biotech Limited shares shed 0.58%, settling at ₹80.48 as the stock tumbled to its 52-week low. The decline was recorded amidst trading volumes of 4,864 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.